Survival of patients with multidrug-resistant TB in Eastern Europe: What makes a difference?

Thorax

Volumn 71, Issue 9, 2016, Pages 854-861

  Balabanova, Yanina ^a,b,c   Ignatyeva, Olga ^d   Fiebig, Lena ^c   Riekstina, Vija ^e   Danilovits, Manfred ^f   Jaama, Kadri ^f   Davidaviciene, Edita ^g   Radiulyte, Birute ^g   Popa, Christina Marcela ^h   Nikolayevskyy, Vladyslav ^a,b   Drobniewski, Francis ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROBERT KOCH INSTITUTE   (Germany)

^d NV Postnikov Samara Region Clinical Tuberculosis Dispensary   (Russian Federation)

^e State Agency Infectology Center of Latvia   (Latvia)

^f TARTU UNIVERSITY HOSPITAL   (Estonia)

^g National Tuberculosis and Infectious Diseases University Hospital   (Lithuania)

^h Marius Nasta Institute of Pneumology   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGING; ALCOHOL ABUSE; ANTIBIOTIC RESISTANCE; ARTICLE; COMORBIDITY; EASTERN EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETIREMENT; SEX DIFFERENCE; SURVIVAL; SURVIVAL TIME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; EPIDEMIOLOGY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; LUNG TUBERCULOSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; RISK FACTOR; SURVIVAL ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EUROPE, EASTERN; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84962890358     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207638     Document Type: Article

References (33)

1. Acosta CD, Dadu A, Ramsay A, et al. Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward. Public Health Action 2014;4:3-12.
2. World Health Organisation. Global Tuberculosis Report. Geneva: WHO/HTM/TB/ 2015.22, 2015.
3. Lucenko I, Riekstina V, Perevoscikovs J, et al. Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006-2010. Public Health Action 2014;4:54-8.
4. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009;7:81-7.
5. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/ extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010;36:584-93.
6. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393-400.
7. Didilescu C, Popescu G, Cioran N, et al. [Mortality of tuberculosis in Romania, a marker for severity of the endemic]. Pneumologia 2012;61:150-2.
8. Zignol M, Dara M, Dean AS, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat 2013;16:108-15.
9. Merker M, Blin C, Mona S, et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 2015;47:242-9.
10. Mokrousov I. Insights into the origin, emergence, and current spread of a successful Russian clone of Mycobacterium tuberculosis. Clin Microbiol Rev 2013;26:342-60.
11. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS report on the global AIDS epidemic 2013 2UNAIDS/JC2502/1/E. Geneva, 2013.
12. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J 2015;45:150-60.
13. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43.
14. Balabanova Y, Radiulyte B, Davidaviciene E, et al. Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study. BMJ Open 2011;1:e000351.
15. Blöndal K, Rahu K, Altraja A, et al. Overall and cause-specific mortality among patients with tuberculosis and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2013;17:961-8.
16. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
17. Keshavjee S, Gelmanova IY, Pasechnikov AD, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008;1136:1-11.
18. Lefebvre N, Falzon D. Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J 2008;31:1256-60.
19. Mathew TA, Yanov SA, Mazitov R, et al. Integration of alcohol use disorders identification and management in the tuberculosis programme in Tomsk Oblast, Russia. Eur J Public Health 2009;19:16-18.
20. Siddiqi S, Ahmed A, Asif S, et al. Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the Bactec MGIT 960 system: a multicenter study. J Clin Microbiol 2012;50:435-40.
21. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68.
22. Casali N, Nikolayevskyy V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 2014;46:279-86.
23. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008;372:1403-9.
24. Kuksa L, Riekstina V, Leimane V, et al. Multi-and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action 2014;4(Suppl 2):47-53.
25. Duraisamy K, Mrithyunjayan S, Ghosh S, et al. Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome?. A population-based study in Kerala, India. Ann Am Thorac Soc 2014;11:712-18.
26. Liang Y, Harris FL, Brown LA. Alcohol induced mitochondrial oxidative stress and alveolar macrophage dysfunction. Biomed Res Int 2014;2014:371593.
27. Shin S, Livchits V, Connery HS, et al. Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia. Addiction 2013;108:1387-96.
28. World Health Organisation. Collaborative action on tuberculosis and alcohol abuse in Estonia: First report of a demonstration project. Copenhagen: WHO, 2013.
29. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-807.
30. Kam KM, Yip CW, Cheung TL, et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006;12:7-11.
31. Miller AC, Gelmanova IY, Keshavjee S, et al. Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation. Int J Tuberc Lung Dis 2012;16:891-6.
32. Glaziou P, Sismanidis C, Floyd K, et al. Global Epidemiology of Tuberculosis. Cold Spring Harb Perspect Med 2014;5:a017798.
33. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014;383:1230-9.